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Aim: Review of literature and adjuvant treatment in Hemangiopericytoma after complete
resection.
Background: Intracranial hemangiopericytoma (HPC) is an uncommon malignant vascular
tumor arising from mesenchymal cells with pericytic differentiation. Surgery remains the
mainstay treatment, and adjuvant radiation therapy appears to be appropriate for patients
with  high grade tumors or incomplete resection. We  present our experience and review of
the literature.
Materials and methods: We  describe two cases of intracranial hemangiopericytoma located
in  the frontal lobe of the CNS. Both patients underwent complete tumor resection followed
by  adjuvant fractionated radiotherapy and completed treatment without interruptions.
Results: A local recurrence was observed in one of these cases and fractionated stereotactic
radiotherapy was performed. Both patients are alive and disease has been under control up
to  date.
Conclusion: The treatment of choice for intracranial hemangiopericytoma is a complete surgi-
cal  resection as long as possible. Adjuvant radiotherapy of HPC can result in increased tumor
control and should be considered as an effective treatment for patients with high grade ordemonstrated residual tumor in the postoperative period. Salvage treatment using limited-
ﬁeld fractionated radiotherapy for local recurrence treatment is considered an acceptable
option.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z.o.o. All
cases of Hemangiopericytomas located in the frontal lobe.  Backgroundntracranial hemangiopericytoma (HPC) is an infrequent
umor with a high tendency to recur and to metastasize
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outside the central nervous system (CNS). We  present twoof the CNS; both patients underwent surgery with complete
resection of tumour followed by an adjuvant fractionated
radiotherapy. A Clinical and radiographic follow up are
ed by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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presented. One with subsequent relapse and salvage radio-
therapy. A review of the literature was performed to conclude
that a limited-ﬁeld fractionated radiotherapy appears to rep-
resent a reasonable approach for postsurgery initial treatment
of HPCs in contrast to other focal techniques.
2. Aim
Treatment of hemangiopericytoma represents a challenging
situation for radiation oncologists. Lack of the literature and
uncertainty of what to do in case of relapse are two aspects
that make these treatments very difﬁcult to decide upon. We
present our experience and review of the literature as an
example in these critical situations.
3.  Introduction
Hemangiopericytomas (HPCs) of the central nervous system
are rare highly cellular and vascularized mesenchymal tumors
exhibiting a characteristic monotonous low-power appear-
ance and a well-developed, variably thick-walled, branching
“staghorn” vasculature. They constitute <1% of all intracranial
tumors and are almost always attached to the Dura. HPCs cor-
respond histologically to WHO  grade II, with anaplastic HPCs
corresponding to WHO  grade III, and at present meningeal HPC
is recognized as a clinicopathologically well-characterized
malignancy distinct from meningioma. HPC cells are diffusely
immunoreactive for vimentin (85%), CD34 (30–100%) and neg-
ative S-100 protein.1
HPCs tend to occur at a younger age than meningiomas
(the mean age at diagnosis, 43 years), and more  often in men
than in women (male/female ratio: 1.4:1).2,3
The symptoms depend on where they are located; it usu-
ally appears with symptoms of intracranial hypertension
(headache, vomiting), less frequently seizures or focal neu-
rological deﬁcits. The average duration of symptoms before
diagnosis ranges from 3 to 6 months.4
Regarding the radiological features, it is virtually impos-
sible to make a differential diagnosis between meningiomas
and HPC based only on images.5,6 Both conditions are often
associated with the meninges (dura mater) and show a very
similar intracranial distribution, however, bone erosion, the
existence of large vessels within the lesion, and brain edema
are typical of the HPCs. In the vast majority of published series
they have been described as single lesions.5–7
As for treatment, the choice is radical excision followed by
postoperative radiotherapy (RTP);2,7–9,11,13
Despite appropriate treatment, HPC exhibits a high ten-
dency for recurrence.11 Early metastases are rare, and increase
over time, reaching 64% at 15 years from the initial approach.2
Overall survival of patients with HPC ranges from 84 to
144 months in most series7,8,2 and is strongly inﬂuenced by
the follow-up time: at 5 years it is 67%, at 10 years, 40% and at
215 years, 23%.
We  present our single institution experience in these types
of tumors discussing fractionation, radiation techniques and
the role of radiotherapy.Fig. 1 – A-B CT axial view. Bifrontal tumor at diagnosis.
4.  Materials  and  methods
We retrospectively reviewed the treatment outcomes, pat-
terns of disease recurrence, and role of radiotherapy in two
patients diagnosed with HPCs treated with total radical exci-
sion followed by postoperative radiotherapy at the Institut
Català d’Oncologia (Spain).
5. Case  A
A 72-year-old woman with no previous medical history of
interest, presented a partial seizure in April 2003. A cra-
nial computed tomography (CT) was performed showing the
presence of a bilateral frontal expansive lesion, well-deﬁned
limits with heterogeneous contrast captures administration
(Fig. 1). These ﬁndings were conﬁrmed by MRI. Surgery was
the initial treatment, and a complete removal of the tumor
was performed. No evidence of further tumor after imme-
diate postoperative CT was detected. Fractionated external
beam radiation therapy was prescribed. A three-dimensional
(3D) limited-ﬁeld planning was used with two  opposite and
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Table 1 – Treatment characteristics.
Parameter Measurement
GTV volume 0.3 cm3
PTV volume 1.09 cm3
Max. dose PTV 26.5 Gy
Min. dose PTV 24.0 Gy
Dosimetry speciﬁcations
Number isocenter 1
Number beams 5
Dose prescribed (100%)/fraction (Gy) 5
Dose prescribed (100%) total (Gy) 25
Limited-ﬁeld radiotherapy was well tolerated by the patients
and completed without interruptions. In both cases, acute
Table 2 – Treatment characteristics.
Parameter Measurement
GTV volume 83.1 cm3
CTV volume 282.0 cm3
PTV volume 427.7 cm3
Max. dose PTV 104.9%
Min. dose PTV 57.3%
Mean dose PTV 99.8%
Number isocenter 1
Number beams 3
Dose prescribed (=100%) 54.0 Gyig. 2 – A-B IMR  axial and coronal view of local recurrence.
arallel lateral ﬁelds using a Varian Clinac® Linear Acceler-
tor 600. The patient was immobilized with a thermoplastic
ead and neck mask for precise repositioning. Fractionation
chedule was 2 Gy/session, ﬁve times a week until a total dose
f 60 Gy.
After 43 months of follow up, the patient being asymp-
omatic, tumor recurrence was found with a lesion of 1 cm
ear the prior tumorectomy region (Fig. 2). Surgical rescue was
uled out by the tumor board, indicating stereotactic fraction-
ted radiotherapy.
The recurrence was treated in January 2007 using a Varian
linac® 600 stereotactic system with a BrainLAB mask. A total
ose of 25 Gy was delivered in 5 Gy per fraction with 6-mV pho-
on. Gross target volume (GTV) was outlined according to MRI
mages, and a 5-mm margin was added to deﬁne CTV plus
 mm to perform the planning target volume (PTV). Critical
rgans and structures including the optic chiasm, brainstem,
yes and left optic nerve were contoured. Dosimetric charac-
eristics are shown in Table 1 and Fig. 3.GTV, gross target volume; PTV, planned target volume; Max., maxi-
mum; Min., minimum.
6.  Case  B
A 48-year-old man  presented with a 2 year history of progres-
sive anosmia, decreased visual acuity and changes in mood.
MRI  images revealed a large bilateral frontal tumor thought to
be a meningioma preoperatively.
In October 2009 the patient underwent a bicoronal cran-
iotomy gross total resection of the tumor.
The microscopic examination revealed tumor cells
immunoreactive to Vimentin, CD34 and CD99, and negative
to S-100 protein, conﬁrming the diagnosis of hemangioperi-
cytoma (WHO grade II) (Fig. 4).
Following surgery using a Varian Clinac® 600, 6-mV pho-
ton, the patient underwent three-dimensional limited-ﬁeld
planning fractionated radiotherapy with a total dose of 54 Gy
at 1.8 Gy/daily fraction. GTV was outlined according to MRI
images fusion, and a 2-cm margin was added to deﬁne the
clinical target volume (CTV), the PTV was deﬁned as more
than 0.5-cm from the CTV. Critical organs and structures were
contoured.
Dosimetric characteristics are shown in Table 2 and Fig. 5.
7. ResultsDose fraction 1.8 Gy
GTV, gross target volume; PTV, planned target volume; Max., maxi-
mum; Min., minimum.
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osimFig. 3 – Treatment plan and dosimetric characteristics. (A) D
toxicity was mild and included skin erytema GI and partial
alopecia GII. To date, no severe late effects have been observed.The range of doses applied for the initial treatment after
the surgery was between 54 and 60 Gy 1.8–2.0/day.
Fig. 4 – Tumor with marked cellularity and monotonous
appearence of the tumor cells. The cells have oval nuclei
with scant cytoplasm. A prominent vascular network is
noted with thin walled vessels with a “staghorn”
appearance. H&E 20×.etric characteristics in relapse area and (B) treatment plan.
In  the Case A, local recurrence was observed at 43 months
after initial treatment of surgery followed by radiotherapy.
Control of initial symptoms was achieved. Reirradiation (frac-
tionated stereotactic radiotherapy) was applied, obtaining a
radiological control in the last follow up. Currently, the patient
is alive with a progression-free survival of 48 months.
In Case B, the patient is 9 months after postoperative
adjuvant radiotherapy, currently, with improvement of initial
symptoms and no radiological signs of recurrence.
8. Discussion
Given the low incidence of HPCs, no multi-institutional
prospective trials can be found to establish standards in adju-
vant radiotherapy.
The attempt to complete surgical excision whenever possi-
ble has remained a standard primary approach in intracranial
HPCs, some authors showing that the extent of resection is
a major factor in local control of this disease.10,11,13 How-
ever, even after gross-total resection, recurrence is common.11
Guthiere et al.2 reported recurrence at a mean of 47 months,
the overall disease recurrence-free (DRF) rates 5 and 10 years
after initial surgery were 65% and 76%, respectively. Alen et al.7
reported a mean time to disease recurrence of 68 months.
Because of the high rate of recurrence, radiotherapy has
been proposed for postsurgical initial treatment of HPCs, even
when a gross-total resection has been achieved.2,11,14,15
The role of radiotherapy in HPCs has proven useful for
local control of the disease and increase in the recurrence-free
interval.2–9 Gutherie et al.2 demonstrated the role of postoper-
ative radiotherapy for intracranial HPCs. Among the 44 cases
described in their series, patients receiving adjuvant radio-
therapy had improved disease-free survival (mean of 75 versus
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 237–242 241
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4 months, p < 0.05), although overall survival was not statis-
ically different, adjuvant radiotherapy extended the survival
eriod from 62 months to 92 months. Dufour et al.9 also found
n their series that local disease recurrence rates for patients
reated with surgery followed by radiotherapy and patients
reated with surgery alone were 12% and 88%, respectively,
nd showed that postoperative radiotherapy provided bene-
t with regard to local disease recurrence. Kim et al.13 did
ot ﬁnd adjuvant radiotherapy to have a statistically signiﬁ-
ant effect on local control, yet they found that 5-year disease
ecurrence-free survival rates associated with complete exci-
ion alone and complete excision with adjuvant radiotherapy
ere 70% and 100%, respectively. More  recently, Soyuer et al.16
eported 5-, 10- and 15-year overall survival rates of 85%, 68%,
nd 43%, respectively, in a series of 29 patients in which 34%
nderwent surgery followed by adjuvant radiotherapy, which
Table 3 – Intracranial hemangiopericytoma series.
Reference No of cases CS% PS% 
Guthiere et al. 2 44 48 39 
Alen et al. 7 12 83 17 
Dufour et al. 9 17 76 24 
Kim et al. 13 31 77 23 
CS, complete surgery; PS, partial surgery; RT, radiotherapy; LR, local recurrsimetrics characteristics.
is comparable with the 5- and 10-year survival rates reported
by Guthiere et al.2 Table 3.
One of the longest follow-up periods (mean follow-up
of 123 m)  in hemangioperycitoma has been published by
Schiariti et al.18. This group found than in patients with a
complete resection who underwent adjuvant external beam
radiotherapy (EBRT) the mean recurrence-free interval was
126.3 months longer than if they did not receive EBRT, also
overall survival was 126 months longer if the received EBRT.
EBRT is the irradiation technique recommended for the
adjuvant treatment of HPCs, dose not less than 50 Gy or more,
usually between 50 and 60 Gy at 1.8–2.0 Gy/day.2–9
Besides the tendency to recur locally, the HPC also recur
throughout the neuraxis, and unlike the majority of primary
intracranial tumors, metastasizes to extraneural sites, several
years later and despite adequate treatment. Most commonly
Adjuvant RT% LR% OS/5 years%
39 66 67
42 33 N/A
47 52 N/A
35 39 96
ence; OS, overal survival.
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to the bone, liver and lungs.2,13,15 This determines the impor-
tance of adequate follow-up in long term.
Stereotactic radiosurgery (SRS) is considered an important
management option for patients with recurrent or residual
intracranial HPCs.10–12 Sheehan et al.10 demonstrated in their
series of 14 patients with recurrent HPC treated with SRS that
at doses >15 Gy (single dose) local control can be achieved in
80% percent of cases. Kano et al.12 with the same single dose
show a progression-free survival (PFS) rate at 5 years was 89%
in recurrent intracranial HPCs; in addition, they found that the
factors associated with improved PFS included lower grade
and higher marginal dose. More  recently, Kim et al.17 ana-
lyzed retrospectively the efﬁcacy of SRS in the treatment of
recurrent intracranial HPCs, achieving similar results to those
reported in other series; however, they demonstrated that
doses higher than previously used (around 15 Gy) are desirable
for better local tumor control of HPCs without severe adverse
radiation effects. The mean tumor volume was 2.2 cm3 and
the mean marginal dose was 18 Gy, the actuarial local control
tumor rates at 1, 2 and 5 years were 100%, 84.6% and 67.7%,
respectively. SRS provides an effective and safe adjuvant
management option for patients with recurrent or residual
HPCs.
9.  Conclusion
HPCs have a high risk of developing disease recurrence, and
represents a major problem. The treatment of choice for
intracranial hemangiopericytoma is a complete surgical resec-
tion whenever technically possible. A collective analysis of
published reports, supports the role of postoperative radio-
therapy in the management of intracranial HPCs. In fact,
adjuvant radiotherapy appears to be a therapeutic factor most
related to the ﬁnal outcome, specially if it is preceded by a total
excision of the tumor. Radiosurgery has been shown to be an
effective treatment for recurrent HPCs.
Although doses above 50 Gy are necessary to control local
disease, given the low incidence of these tumors, there is no
standard treatment guidelines based on evidence that support
the choice of a speciﬁc type of radiation treatment technique.
In our experience, salvage treatment using limited-ﬁeld
fractionated radiotherapy of local recurrence was imple-
mented, obtaining good results in terms of progression-free
survival.
Overall and progression-free survival times of patients with
HPCs have been improved with time. However, there is no spe-
ciﬁc treatment of HPC, which remains a great challenge for
oncologists to research and publish their experience with new
cases so as to provide us with scientiﬁc support and bases for
speciﬁc treatment of these types of tumors.Conﬂict  of  interest
None declared.
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